Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug

Viridian Therapeutics, Inc.\DE

Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.
WuXi Biologics is non-exclusive supplier; Viridian may use alternate manufacturers.
Initial term of 5 years, auto-renewing for successive 5-year periods unless 24-month non-renewal notice given.
Volume-based pricing fixed through Dec 31, 2026, then annually adjustable; pass-through costs reimbursed.
Company may terminate on 30 days' notice for change in law materially impacting WuXi's performance.

item 1.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-239246
form_type: 8-K
ticker: VRDN
cik: 0001590750
company_name: Viridian Therapeutics, Inc.\DE
filed_at: 2026-05-26T20:05:16+00:00
discovered_at: 2026-05-26T20:07:00.525074+00:00
generated_at: 2026-05-26T20:50:39.516726+00:00
sec_items: ["1.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-239246
json_url: https://secwatch.observer/filing/0001193125-26-239246.json
markdown_url: https://secwatch.observer/filing/0001193125-26-239246.md
text_url: https://secwatch.observer/filing/0001193125-26-239246.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/0001193125-26-239246-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-239246

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.